T. Rowe Price Investment Management, Inc. Moon Lake Immunotherapeutics Transaction History

T. Rowe Price Investment Management, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$43.78 - $63.86 $5.49 Million - $8.01 Million	-125,501 Reduced 10.28%	1,095,101 $55 Million
Q4 2023 Feb 14, 2024	BUY	$36.35 - $63.02 $213,701 - $370,494	5,879 Added 0.48%	1,220,602 $73.7 Million
Q3 2023 Nov 14, 2023	BUY	$48.35 - $61.26 $3.19 Million - $4.04 Million	65,914 Added 5.74%	1,214,723 $69.2 Million
Q2 2023 Aug 14, 2023	BUY	$19.01 - $51.79 $21.8 Million - $59.5 Million	1,148,809 New	1,148,809 $58.6 Million

124

58.2M

52.2K

38K

Ticker MLTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,925,600
Market Cap $1.93B
Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...

Get notified when there are updates to the investment portfolio of T. Rowe Price Investment Management, Inc., based on Form 13F filings with the SEC.

Stay updated on T. Rowe Price Investment Management, Inc. with notifications on news.